

WITH THE SUPPORT AND ENDORSEMENT OF:



under the patronage  
of the European Parliament



# Driving Collaboration in the Fight against Antimicrobial Resistance: Going Further, Aiming Higher

15 NOVEMBER, 11AM-12.30PM CET  
EUROPEAN PARLIAMENT, ROOM A3E-2 (HYBRID)

SPONSORED BY:



# Background

The policy roundtable, hosted by MEP Aldo Patriciello (EPP, Italy), aims to raise awareness of the urgent need to leverage current EU policy developments in the fight against Antimicrobial Resistance (AMR). In the aftermath of the COVID-19 pandemic, AMR is set to become an increasing threat to the resilience of healthcare systems and places a significant burden on society in Europe and beyond. Ahead of World Antimicrobial Awareness Week (18-24 November) and supported by the MEP Interest Group on European Patients' Rights & Cross-Border Healthcare, Shionogi Europe convenes high-level stakeholders from across the healthcare spectrum, including policymakers, patient advocacy groups, academia and industry to discuss how we can collectively raise the stakes in the fight against AMR.

Closer collaboration on health in the context of the European Health Union and the forthcoming revision of the EU pharmaceutical legislation creates new opportunities to create synergies across borders to drive innovation in the development of effective antibiotics. Drawing on best practices on spearheading innovation in the fight against AMR and beyond, amongst others COVID-19, the policy roundtable will identify actionable solutions to address unmet needs and improve implementation locally. Against this background, speakers will also share their perspective on new ways of governance and multi-stakeholder collaboration to ensure action is holistic and resourceful for better impact.

# Objectives

The overall objective of this event is to raise awareness of unmet needs in the fight against AMR as well as to identify and implement tangible policy action across EU Member States to result in behavioural and societal change.

## Panel discussion 1: Incentivising innovation in AMR

---

- Discuss how the revision of the EU pharmaceutical legislation and other EU initiatives can be leveraged to spur innovation to ensure people have access to safe and effective new antibiotics.
- Learn from national best practices to create the right conditions for innovation to benefit patients and address unmet needs in AMR.
- Identify practical solutions to ensure policy action against AMR results in concrete outcomes for society and healthcare systems.

## Panel Discussion 2: Looking ahead – driving sustainable collaborations to address unmet needs

---

- Discuss lessons learnt from the COVID-19 pandemic and other health crises to implement an actionable and holistic model for collaboration in the fight against AMR.
- Identify synergies across global and European health policy frameworks to collectively tackle AMR through a comprehensive approach addressing innovation, training & education and human and animal health.

# Agenda

## 15' Opening remarks

- Moderator, Vivienne Parry
  - Video from MEP Aldo Patriciello and MEP István Ujhelyi
  - MEP Fabio Massimo Castaldo
  - Mariano Votta, Director, Active Citizenship Network
- 

## 35' Panel discussion 1: Incentivising innovation in AMR

- Nobuko Ichikawa, Senior Environmental and AMR Consultant for the European Bank for Reconstruction and Development (EBRD)
  - Christine Oline Årdal, Norwegian Public Health Institute (virtual)
  - Aleksandra Opalska, DG SANTE, European Commission (virtual)
- 

## 30' Panel Discussion 2: Looking ahead – driving sustainable collaborations to address unmet needs

- Jan De Maeseneer, Chair of the Expert Panel on effective ways in investing in health (virtual)
  - Cristina Muñoz Madero, Head of Clinical and Pre-Clinical Area, Coordinator of the Spanish National Plan on AMR, Spanish Agency for Medicines and Medical Devices, AEMPS (virtual)
  - Keiko Tone, UK General Manager, Shionogi
- 

## 10' Concluding remarks

- Final thoughts from all panellists

# Speakers' Biographies



**Prof. Jan De Maeseneer**  
CHAIR OF THE EXPERT PANEL  
ON EFFECTIVE WAYS IN  
INVESTING IN HEALTH

Prof. Jan De Maeseneer, MD, PhD, (Hon) FRCGP, is the Director of the International Centre for Primary Health Care and Family Medicine – Ghent University, a WHO Collaborating Centre on Family Medicine and Primary Health Care. Prof. Jan De Maeseneer is the Chair of the Expert Panel on Effective Ways of Investing in Health, advising the European Commission on critical health challenges. Since 2019, he has also been an International Member of the National Academy of Medicine (Washington, USA).

Simultaneously, he is contributing to the Primafamed-Network (<https://primafamed.sun.ac.za/>), a network focusing on capacity-building for human resources for primary health care in Africa. He currently is a member of the Advisory Board of the European Forum for Primary Care (<http://www.euprimarycare.org/>) and has been the Secretary-General of The Network: Towards Unity for Health from 2007 – 2015.

Prof. De Maeseneer has been the Chair of the Strategic Advisory Board for Welfare, Health and Family, advising the Flemish Minister from 2010-2018. He has been the Head of Department of Family Medicine and Primary Health Care at Ghent University (1991-2017) and Vice-Dean for Strategic Planning at the Faculty of Medicine and Health Sciences (2008-2017). He has worked from 1978-2017 as a family physician in the inter-professional Community Health Center Botermarkt – Ledeborg (Ghent – Belgium).



**Christine Årdal**  
NORWEGIAN PUBLIC HEALTH  
INSTITUTE

Christine Årdal, MBA, PhD has worked for over 25 years on access to medicines through different sectors, including research institutes, governmental development assistance, pharmacy, national health services and insurance. At the Norwegian Institute of Public Health, her research focuses on the policy aspects of antimicrobial access and innovation.

Årdal was previously the co-lead of the research and innovation work package for the European Union's Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI), which aimed to detail European strategies to implement mechanisms to increase antibiotic and alternative therapeutic innovation. She was also a co-lead in the DRIVE-AB research project which aimed to transform the way policymakers stimulate innovation, the sustainable use, and the equitable availability of novel antibiotics to meet unmet public health needs.

She is the co-lead for the Programme Committee of the Oslo Medicines Initiative, aiming to improve access to innovative, high-priced medicines, and an active member of the Norwegian assessment of local production for critical antibiotics and the MIA-research project, examining supply chain solutions to improve access to medicines.



**Maria Jesús Lamas Díaz**  
DIRECTOR, SPANISH AGENCY  
FOR MEDICINES AND  
MEDICAL DEVICES

María Jesús Lamas Díaz has been the Director of the Spanish Agency for Medicines and Medical Devices (AEMPS) since 2018. She is also a member of the coordinating group of the Head of Medicine Agencies (HMA) and of the Management Board of the European Medicines Agency (EMA). Ms. Díaz represents Spain on the Steering Board of the European Vaccine Strategy led by the European Commission.

Until she took office as Director of the AEMPS, she directed the Pharmacy Service of the Santiago University Hospital Complex (CHUS), while coordinating the Platforms and Methodology Area of the Santiago Health Research Institute (IDIS – ISCIII). In addition, she was Research Director of the Spanish Society of Hospital Pharmacy (SEFH) from 2012 to 2016.

A Doctor of Pharmacy (extraordinary award) from the University of Santiago de Compostela, she is a specialist in hospital pharmacy and is accredited as a clinical pharmacist in Oncology by the Board of Pharmaceutical Specialties (BPS) and the American Pharmaceutical Association (APhA). In her research role, she has led the IDIS - SCIII Clinical Pharmacology Research Group and has served as principal investigator for 12 projects.



**Nobuko Ichikawa**  
SENIOR ENVIRONMENTAL &  
AMR CONSULTANT

Nobuko Ichikawa is a senior consultant on AMR & environment. She was working in the European Bank for Reconstruction and Development (EBRD) since 1996 where she served as a senior environmental advisor/associate director in the Environment Department until her retirement in 2022. Before, she had worked in the World Bank in Washington D.C. from 1991 to 1996. Her current focus on AMR initiatives is to effectively recognise risks and take adequate mitigation measures at project level as well through policy dialogue. With EBRD She supported EBRD's AMR risk management audits and trainings for its client hospitals in Georgia, Turkey, Ukraine and Egypt as well as the inclusion of specific AMR references in the 2019 Environmental & Social Policy.

Her work in EBRD also involved environmental due diligence for healthcare services, Public-Private Partnership hospital facilities, property and tourism, information technologies/telecommunication, urban redevelopment and cultural heritage and social inclusion in EBRD countries of operations. With the World Bank, she worked on industrial pollution prevention policies in Vietnam, Thailand and Malaysia. She obtained a Master's Degree in urban studies and city planning at MIT in Cambridge, M.A. USA.



**Keiko Tone**  
UK GENERAL MANAGER  
SHIONOGI

Shionogi is a leader in the development of medicines to treat infectious diseases. Shionogi's recent success is the development of a new antimicrobial that targets multidrug resistant Gram-negative bacteria. Shionogi has also discovered multiple antiviral medicines, including treatments for influenza and integrase inhibitors for the treatment of HIV, and continue to focus on emerging and re-emerging conditions caused by infectious agents.

Keiko has been working closely with the NICE (the National Institute for Health and Care Excellence)/NHSE (NHS England) team for the development and implementation of the antimicrobial "de-linkage" scheme currently in its pilot phase in England. She is also the chair of ABPI (Association of British Pharmaceutical Industry) AMR Interest Group leading the industry to work with the UK government to create the optimal future scheme beyond the pilot phase.

Earlier at Shionogi as EU Head of Market Access and Policy, she has led multiple successful value and access negotiations of an antimicrobial in several EU countries, including a pilot scheme in Sweden. Prior to joining Shionogi, she worked for Biotronik (European medical device company) and McKinsey and Company in Europe and in Japan.

She grew up in Japan and holds a BA in Mathematical Sciences from the University of Oxford and an MBA from INSEAD Business School.



**Mariano Votta**  
DIRECTOR, ACTIVE  
CITIZENSHIP NETWORK

Mariano Votta is responsible for EU Affairs at the Italian NGO Cittadinanzattiva and Director of its EU branch called "Active Citizenship Network". committed at the EU level to increase the protection of patients' rights and their involvement in the decision-making process. In this role, he oversees Public Affairs and Project Management at the EU level.

Mariano has over 20 years of experience in advocacy, stakeholder engagement, European projects, communication, and civic information. He began his career working in journalism as Communication Officer at Cittadinanzattiva; in this position, he was involved at the international level within the United Nations Development Programme, where he worked as a consultant in Public Services and Communication in Colombia. He then moved on to take up his current position within ACN; since then, he has been actively involved as ACN stepped up its advocacy activities at the EU Institutions, which led to the opening of a representative office in Brussel in 2014. After that, he led the political initiative to launch in 2015 the MEP Interest Group "EU Patients' Rights & Cross-Border Healthcare," endorsed by nearly 100 organisations across Europe, and the MEP Interest Group "SDGs for wellbeing and consumer protection" in 2021.

In 2022 he has been officially appointed by the EU Commission as a member of the HERA Civil Society Forum, the expert group of the HERA Advisory Forum, led by the European Health Emergency preparedness and Response Authority (HERA). In 2016 Mariano has won the Efhre International University Excellence Awards on patients' rights and in 2017 he was appointed as Secretary-General at European Consumer Union. Along the mandate 2016/2019, he was also appointed by the EU Commission to represent Italian Consumer Associations in the EU Consumer Consultative Group.



**Aleksandra Opalska**  
POLICY OFFICER, DG SANTE,  
EUROPEAN COMMISSION

Aleksandra Opalska is a policy officer at the European Commission in the Directorate-General for Health and Food Safety in the unit responsible for medicines: policy, authorisation and monitoring. She works on antimicrobial resistance, the lessons learned from the COVID-19 pandemic and pharmacovigilance related activities. She is a pharmacist by training and has published a study on "Enabling appropriate use of antibiotics: review of European Union procedures of harmonizing product information, 2007 to 2020".



**Vivienne Parry**

Vivienne Parry is a British science writer and broadcaster. A scientist by training, Vivienne hosts medical programmes for BBC Radio 4, writes widely on health, presents films and facilitates many high-level conferences. She also has a part time role as Head of Public Engagement at Genomics England which delivered the 100,000 Genomes Project. She has recently completed her terms on the Board of UKRI, the body responsible for the strategic spend of Britain's £7 billion annual research budget. She has always had a keen interest in AMR, presenting a number of films and programmes on it.



**MEP Fabio Massimo Castaldo**

Fabio Massimo Castaldo was first elected to the European Parliament in 2014, where he was subsequently appointed Vice-President in 2017, as the youngest Vice-President in the history of the European Parliament. Prior to being elected in the European Parliament, he served as a Parliamentary assistant at the Italian Senate (2013-2014). In the Parliament, he is a member of Committee on Foreign Affairs, the Subcommittee on Security and Defence and the Delegation for relations with the Maghreb countries and the Arab Maghreb Union, including the EU-Morocco, EU-Tunisia and EU-Algeria Joint Parliamentary Committees, as well as the Delegation to the Euro-Latin American Parliamentary Assembly.

MEP Castaldo holds a double degree in Italian and French law, and a Master's degree in law, from Tor Vergata University of Rome. He also holds a Masters' degree in international and European law from Paris-Est University.



MEP Aldo Patriciello

MEP Aldo Patriciello has been a Member of the Christian Democrats in Italy since 1979, responsible for the regional Youth Movement. Simultaneously, he has been a Member of the Regional Secretariat of the UDC Party; member of the National Directorate of the UDC Party, and he served as the local administrator of the Local Council of Venafro (Isernia) from 1983 to 1995. He has also served as the Regional Counsellor of the Italian region of Molise (1995-2006), the Vice President of the Regional Council, and as the Councillor responsible for budget, transport, agriculture and economic activities in the region of Molise.

In the European Parliament, he is a member of the Committee on Industry, Research and Energy, and a substitute member of the Committee on Environment, Public Health and Food Safety, the Special Committee on the COVID-19 pandemic: lessons learned and recommendations for the future, and the Delegation to the EU-Russia Parliamentary Cooperation Committee.



MEP István Ujhelyi

MEP Istvan Ujhelyi was elected as a Member of the European Parliament following the 2014 elections. Prior to being elected to the European Parliament, he has served in a variety of positions in the national government, such as State Secretary in the Prime Minister's Office (2009-2010), Chair of the National Tourism Committee (2009-2010), a State Secretary in the Ministry for Local Government and Regional Development (2006-2008) and a Senior Adviser to the Prime Minister (2002-2004).

He has also held roles in the Hungarian parliament, such as Deputy Speaker of the Hungarian National Assembly (2010-2014), a Member of the Committee on European Affairs, the Committee on Culture and Media and the Committee on Youth Affairs and Vice-Chair of the Committee on Youth and Sport (2002-2006).

Since his election to the European Parliament, he has been serving as Vice-Chairman of the Committee on Transport and Tourism in the European Parliament, and he is also a substitute member of the Committee on the Environment, Public Health and Food Safety, as well as of the Delegation for relations with the People's Republic of China.

MEP Ujhelyi holds a Law degree from József Attila University, Szeged.

## About Shionogi

Shionogi B.V. is a leading global research-driven pharmaceutical company based in Osaka, Japan. Since 1878, Shionogi has been striving to supply the best possible medicines to protect the health and wellbeing of the patients we serve.

Shionogi Europe's registered office is in Amsterdam. We have an established UK office, where we carry out centralised operational and administrative support functions for Europe, and three subsidiaries in Italy, Spain and Germany.

Shionogi is committed to putting patients first by developing innovative, high-quality medicines which address their unmet needs and improve the quality of their lives. R&D efforts focus on therapeutic areas where we have proven expertise and can make an impact. These include: infectious disease, haematology, women's health, pain & CNS disorders.

We are proud to have delivered treatments in these therapeutic areas and aim to find even better solutions to major global public health concerns using our advanced scientific know-how, talented people and passion. Our values are at the heart of everything we do. They define our culture, shape our collaborative approach to R&D, and guide our decision-making so that we can achieve our global vision of "building innovation platforms to shape the future of healthcare".

Our logo is a stylised fundoh, which is a traditional device used for measuring medicine weight. The fundoh represents accuracy, reliability and trustworthiness, and reflects the trust that has been placed in Shionogi over the years by patients, healthcare providers, our industry collaboration partners, regulators, the pharmaceutical industry, and society.

## About Antimicrobial Resistance

Antimicrobial Resistance (AMR) – the ability of microorganisms to resist antimicrobial treatments, especially antibiotics – places a considerable burden on healthcare systems, society and animal health. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become increasingly difficult or impossible to treat.<sup>1</sup>

According to a WHO Technical Report, in 2019 AMR directly caused nearly 1.3 million deaths and was associated with almost 5 million deaths.<sup>2</sup> The European Health Union indicated antimicrobial resistance (AMR) as one of its top three priority health threats in the EU requiring urgent attention and action.

<sup>1</sup> WHO factsheet on AMR. Last consulted on 26 October at <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>

<sup>2</sup> Bacterial vaccines in clinical and preclinical development 2021: An overview and analysis. Last consulted on 13 July 2022 at <https://www.who.int/publications/item/9789240052451>

WITH THE SUPPORT AND ENDORSEMENT OF:



under the patronage  
of the European Parliament



EU2022.CZ

SPONSORED BY:

